- Revenue $12.14B, +9% YoY, beat $11.95B estimate
Thermo Fisher Scientific beat Q3 estimates with $12.14B revenue (+9% YoY) and $6.68 adjusted EPS (+15% YoY). Organic growth was 6%. Adjusted operating margin rose 120 bps to 24.5%. Free cash flow was $2.12B. The company completed its microbiology divestiture. Updated 2026 guidance is expected on the morning call.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.